Claims
- 1. A compound of the formula ##STR301## or a pharmaceutically acceptable acid addition salt thereof, wherein: n is an integer from 0 to 10 inclusive;
- R is --CH.sub.2 --X--R.sub.2 wherein X is SO, SO.sub.2 and R.sub.2 is C.sub.1 -C.sub.7 alkyl or C.sub.3 -C.sub.12 cycloalkyl; ##STR302## wherein R.sub.2 is defined as above; or ##STR303## wherein X is defined as above and wherein R.sub.3 is C.sub.1 -C.sub.7 alkyl and R.sub.4 is C.sub.1 -C.sub.7 alkyl or wherein R.sub.3 and R.sub.4 together represent --(CH.sub.2).sub.m --wherein m is 3 or 4 and --(CH.sub.2)--.sub.m is optionally substituted by one to three C.sub.1 -C.sub.7 alkyl;
- R.sub.1 is C.sub.1 -C.sub.7 alkyl;
- and Ar is a divalent radical selected from the group consisting of:
- (a) unsubstituted phenylene; and
- (b) phenylene substituted by C.sub.1 -C.sub.7 alkyl, C.sub.1 -C.sub.7 alkyl--O--C.sub.1 --C.sub.7 alkylene-, C.sub.2 -C.sub.8 alkenyl, C.sub.1 -C.sub.7 alkyl-S-, C.sub.2 -C.sub.8 alkenyl-O-, C.sub.3 -C.sub.12 cycloalkyl, C.sub.1 -C.sub.7 -alkyl-CONH-, C.sub.1 -C.sub.7 alkyl-CO- or H.sub.2 NCO-C.sub.1 -C.sub.7 alkylene-.
- 2. The compound as defined by claim 1, wherein n is zero, one or two.
- 3. A method for eliciting a .beta.-adrenergic blocking response in a warm-blooded animal, which comprises administering to said animal an effective .beta.-adrenergic blocking amount of a compound of formula (I) as defined by claim 1, or a pharmaceutically acceptable acid addition salt thereof.
- 4. A pharmaceutical composition of matter, in unit dosage form, for use in eliciting a .beta.-adrenergic blocking response in a warm-blooded animal, said composition comprising, per dosage unit, an effective unit .beta.-adrenergic blocking amount of a compound of formula (I) as defined by claim 1 or a pharmaceutically acceptable acid addition salt thereof, and a non-toxic pharmaceutically acceptable carrier therefor.
- 5. A method for the treatment of glaucoma or for lowering intraocular pressure in a warm-blooded animal, which comprises administering to the eye or the eyes of said animal an effective intraocular pressure decreasing amount of a compound of formula (I) as defined by claim 1, or a pharmaceutically acceptable acid addition salt thereof.
- 6. An ophthalmic composition of matter, in unit dosage form, for use in the treatment of glaucoma or in the lowering of intraocular pressure in a warm-blooded animal, said composition comprising, per dosage unit, an effective unit intraocular pressure decreasing amount of a compound of formula (I) as defined by claim 1 or a pharmaceutically acceptable acid addition salt thereof, and a non-toxic ophthalmically acceptable carrier therefor.
- 7. A compound of the formula ##STR304## or a pharmaceutically acceptable acid addtion salt thereof, wherein: n is an integer from 0 to 10 inclusive;
- R is --CH.sub.2 --X--R.sub.2 wherein X is S, SO or SO.sub.2 and R.sub.2 is C.sub.1 -C.sub.7 alkyl or C.sub.3 -C.sub.12 cycloalkyl;
- R.sub.1 is C.sub.1 -C.sub.7 alkyl;
- and Ar is a divalent radical selected from the group consisting of:
- (a) unsubstituted phenylene; and
- (b) phenylene substituted by C.sub.1 -C.sub.7 alkyl, C.sub.1 -C.sub.7 alkyl-O-C.sub.1 -C.sub.7 alkylene-, C.sub.2 -C.sub.8 alkenyl, C.sub.1 -C.sub.7 alkyl-S-, C.sub.2 -C.sub.8 alkenyl-O-, C.sub.3 -C.sub.12 cycloalkyl, C.sub.1 -C.sub.7 -alkyl-CONH-, C.sub.1 -C.sub.7 alkyl-CO- or H.sub.2 NCO-C.sub.1 -C.sub.7 alkylene-.
- 8. The compound as defined by claim 7, wherein n is zero, one or two.
- 9. The compound as defined by claim 7, wherein R.sub.2 is C.sub.1 -C.sub.7 alkyl.
- 10. The compound as defined by claim 9, wherein R.sub.2 is methyl.
- 11. The compound as defined by claim 7, wherein Ar is a divalent radical selected from the group consisting of:
- (a) unsubstituted 1,4- or 1,3-phenylene; and
- (b) phenylene substituted by a CH.sub.3 CH.sub.2 --, CH.sub.3 --, CH.sub.3 OCH.sub.2 CH.sub.2 --, Ch.sub.2 =CH--CH.sub.2 --, CH.sub.3 --S--, CH.sub.2 CH=CH.sub.2 --O--, ##STR305## CH.sub.3 CH.sub.2 CH.sub.2 CONH--, Ch.sub.3 CONH--, CH.sub.3 CO--or H.sub.2 NCO--CH.sub.2 --.
- 12. The compound as defined by claim 7, wherein Ar is unsubstituted phenylene.
- 13. The compound as defined by claim 12, wherein Ar is 1,4-phenylene or 1,3-phenylene.
- 14. The compound as defined by claim 7, wherein R.sub.1 is isopropyl or tert-butyl.
- 15. The oxalate salt of a compound as defined by claim 7.
- 16. The compound as defined by claim 7, said compound being selected from the group consisting of the compounds of the formula ##STR306## and the pharmaceutically acceptable acid addition salts thereof.
- 17. The compound as defined in claim 64, having the formula ##STR307##
- 18. A method for eliciting a .beta.-adrenergic blocking response in a warm-blooded animal, which comprises administering to said animal an effective .beta.-adrenergic blocking amount of a compound of formula (I) as defined by claim 7, or a pharmaceutically acceptable acid addition salt therof.
- 19. A pharmaceutical composition of matter, in unit dosage form, for use in eliciting a .beta.-adrenergic blocking response in a warm-blooded animal, said composition comprising, per dosage unit, an effective unit .beta.-adrenergic blocking amount of a compound of formula (I) as defined by claim 7 or a pharmaceutically acceptable acid addition salt thereof, and a non-toxic pharmaceutically acceptable carrier therefor.
- 20. A method for the treatment of glaucoma or for lowering intraocular pressure in a warm-blooded animal, which comprises administering to the eye or the eyes of said animal an effective intraocular pressure decreasing amount of a compound of formula (I) as defined by claim 7, or a pharmaceutically acceptable acid addition salt thereof.
- 21. An ophthalmic composition of matter, in unit dosage form, for use in the treatment of glaucoma or in the lowering of intraocular pressure in a warm-blooded animal, said composition comprising, per dosage unit, an effective unit intraocular pressure decreasing amount of a compound of formula (I) as defined by claim 7 or a pharmaceutically acceptable acid addition salt thereof, and a non-toxic ophthalmically acceptable carrier therefor.
Priority Claims (1)
Number |
Date |
Country |
Kind |
476391 |
Mar 1985 |
CAX |
|
Parent Case Info
This application is a division of application Ser. No. 07/692,260, filed Apr. 26, 1991, now U.S. Pat. No. 5,125,926, which is a continuation of application Ser. No. 07/286,879, filed Dec. 20, 1988 now abandoned, which is a division of application Ser. No. 06/922,462, filed Oct. 23, 1986 now U.S. Pat. No. 4,829,086, which is a continuation of application Ser. No. 06/741,846, filed June 6, 1985 now abandoned, which is a continuation-in-part of my earlier copending application Ser. No. 589,359, filed Mar. 14, 1984 now abandoned, incorporated by reference herein in its entirety and relied upon.
US Referenced Citations (8)
Foreign Referenced Citations (4)
Number |
Date |
Country |
0041491 |
Dec 1981 |
EPX |
59-118746 |
Jul 1984 |
JPX |
8201869 |
Jun 1982 |
WOX |
8301772 |
May 1983 |
WOX |
Non-Patent Literature Citations (2)
Entry |
Bodor et al, Pharmaceutical Research, 1984, No. 3, 120-125. |
Erhardt et al, J. Med. Chem., 1982, vol. 25, No. 12, 1408-1412. |
Divisions (2)
|
Number |
Date |
Country |
Parent |
692260 |
Apr 1991 |
|
Parent |
922462 |
Oct 1986 |
|
Continuations (2)
|
Number |
Date |
Country |
Parent |
286879 |
Dec 1988 |
|
Parent |
741846 |
Jun 1985 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
589359 |
Mar 1984 |
|